Has Amanda Finlayson received payments from drug or device companies?

Yes. Drug and device makers reported $8,085 in general payments to Amanda Finlayson across 279 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amanda Finlayson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amanda Finlayson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amanda Finlayson

Family · Gilbert, AZNPI 1740773829

Payments from drug & device makers

$8,085in general payments, 2019–2025

Across 279 payments — averaging $28.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$1K
Astellas Pharma US Inc$785
Seagen Inc.$755
AstraZeneca$524
Novartis$502
Pfizer$311
plus $4K from 54 others

What the payments were for

Food & beverage$5,76271%
Education$2,32329%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	39	$1,033
Astellas Pharma US Inc	14	$785
Seagen Inc.	15	$755
AstraZeneca(2 entities)	14	$524
Novartis	24	$502
Pfizer	14	$311
Merck	14	$303
Takeda Pharmaceuticals U.S.A., Inc.	7	$289
Daiichi Sankyo Inc.	9	$274
GSK	12	$272
AVEO Pharmaceuticals, Inc.	6	$237
Incyte Corporation	8	$227
Gilead(2 entities)	5	$167
Sanofi-aventis U.S. LLC	2	$165
Bayer	7	$150
AbbVie	6	$116
Sanofi	4	$96
Adaptive Biotechnologies Corporation	2	$89
KCI USA, Inc.	4	$85
Ipsen Biopharmaceuticals, Inc	2	$80
Taiho Oncology, Inc.	3	$80
Tersera Therapeutics LLC	2	$79
Pharmaessentia USA Corporation	3	$77
Progenics Pharmaceuticals, Inc.	3	$72
EMD Serono, Inc.	3	$71
Regeneron Healthcare Solutions, Inc.	3	$67
E.r. Squibb & Sons, L.L.C.	3	$65
Lilly USA, LLC	2	$59
Bristol Myers Squibb	3	$58
Pharmacosmos Therapeutics Inc.	2	$54
Mirati Therapeutics, Inc.	3	$54
Jazz Pharmaceuticals Inc.	2	$50
Legend Biotech USA Inc.	2	$49
Stemline Therapeutics Inc.	2	$48
Sobi, Inc	2	$45
Amgen	2	$44
Azurity Pharmaceuticals, Inc.	2	$43
Ferring Pharmaceuticals Inc.	2	$43
Rigel Pharmaceuticals, Inc.	2	$42
Boston Scientific	2	$42
Caris MPI, Inc.	2	$39
Beigene USA, Inc.	2	$39
Tolmar, Inc.	2	$36
Syndax Pharmaceuticals, Inc.	1	$32
Tactile Systems Technology Inc	1	$29
Helsinn Therapeutics (U.S.), Inc.	1	$28
Genmab U.S., Inc.	1	$25
Tolmar Pharmaceuticals, Inc.	1	$25
Boehringer Ingelheim	1	$24
Deciphera Pharmaceuticals Inc.	1	$24
Tempus AI, Inc	1	$24
Coherus Oncology, Inc.	1	$22
Puma Biotechnology, Inc.	1	$22
Accord Healthcare, Inc.	1	$19
Pharmacyclics LLC, An Abbvie Company	1	$17
Eisai Inc.	1	$17
Verity Pharmaceuticals Inc.	1	$16
Alnylam Pharmaceuticals Inc.	1	$16
Immunocore Limited	1	$15
Blueprint Medicines Corporation	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LYNPARZA$244
Erleada$120

How this compares

$8,085 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	50	$35,653
Oxycodone Hcl	69	$2,090
Fluconazole	27	$1,685
Ondansetron OdtOndansetron	58	$1,575
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	12	$949
Prochlorperazine Maleate	45	$762
Morphine Sulfate ErMorphine Sulfate	23	$716
Dexamethasone	37	$613
Acyclovir	43	$572
Lactulose	16	$314
Levofloxacin	22	$234
Warfarin Sodium	16	$203
Lidocaine-PrilocaineLidocaine/Prilocaine	13	$147
Pantoprazole Sodium	18	$122
Prednisone	28	$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$311	$35,65350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Gilbert

Celeste FineGilbert$82K
Rechelle TrejoGilbert$34K
Jonathan HenriquezGilbert$26K
Arin LamoureauxGilbert$17K
Sharon MagalonaMesa$449K
Angela GoldenMunds Park$378K
Kimberly HallaPhoenix$332K
Kaitlyn LouchheimScottsdale$208K
Rebecca McCollaumMesa$149K
Susan SarabiaSun City West$114K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →